Abstract:Aim: Inflammation is a critical component of tumor progression. Lipoxin A(4) (LXA(4)) has been approved for potent anti-inflammatory properties. Recently, it was reported that LXA(4) repressed the expression and activity of cyclooxygenase-2 (COX-2), which is essential for invasion. However, there are few reports dealing with its effects on cancer. To explore whether LXA(4) regulate invasion, the effects of LXA(4) and its receptor agonist BML-111 on hepatocyte growth factor (HGF)-induced invasion of hepatoma cells and the possible mechanisms were researched. Methods: Lipoxin A(4) receptor (ALX) expression in HepG2 cells were measured through reverse transcription polymerase chain reaction and western blot. Cytotoxicity of LXA(4) and BML-111 to HepG2 cells was detected by MTT and (H-3)-TdR incorporation assay. Cell migration and invasion assays were performed using a Boyden chemotaxis chamber. COX-2 expression was detected by real-time polymerase chain reaction and western blot, respectively. Moreover, the expressions of matrix metalloproteinases (MMP)-2, MMP-9, I kappa B alpha and nuclear factor-kappa B (NF-kappa B) p65 were observed via western blot, and NF-kappa B transcriptional activity was tested by transfections and luciferase activities assay. Results: ALX expression was detected in HepG2 cells, and suitable concentrations of LXA(4) and BML-111 had no cytotoxicity to cells. LXA(4) and BML-111 inhibited HGF-induced migration and invasion; downregulated COX-2, MMP-2 and -9; restrained HGF-induced I kappa B alpha degradation, NF-kappa B translocation and the transcriptional activity of NF-kappa B in HepG2 cells. Furthermore, exogenous PGE2 could reverse the inhibitory effects of LXA(4) also BML-111 on HGF-induced invasion and migration partially. Conclusion: LXA(4) inhibited HGF-induced invasion of HepG2 cells through NF-kappa B/COX-2 signaling pathway partially.

BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells

BML-111, the agonist of lipoxin A4, suppresses epithelial-mesenchymal transition and migration of MCF-7 cells via regulating the lipoxygenase pathway

Lipoxin A(4) and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: the Role of Antiangiogenesis

Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma

Effects of Lipoxin A<sub>4</sub> on CoCl<sub>2</sub>-Induced Angiogenesis and Its Possible Mechanisms in Human Umbilical Vein Endothelial Cells

Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells.

BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway

Lipoxin A(4) and Its Analog Suppress Hepatocarcinoma Cell Epithelial-Mesenchymal Transition, Migration and Metastasis Via Regulating Integrin-Linked Kinase Axis

Protective Effects of Bml-111, A Lipoxin A(4) Receptor Agonist, on Carbon Tetrachloride-Induced Liver Injury in Mice

Lipoxin A4Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer

Effects of lipoxin A4 on hepatocyte growth factor-induced angiogenesis-related cytokines in HepG2 cells

BML-11, A Lipoxin Receptor Agonist, Protected Carbon Tetrachloride-Induced Hepatic Fibrosis in Rats

Lipid Mediator Lipoxin A4 Inhibits Tumor Growth by Targeting IL-10-producing Regulatory B (breg) Cells.

Lipoxin A4 and Its Analog Suppress Hepatocellular Carcinoma Via Remodeling Tumor Microenvironment

Supplementary Figure 1 from Lipoxin A<sub>4</sub> and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: the Role of Antiangiogenesis

Supplementary Figure 3 from Lipoxin A<sub>4</sub> and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: the Role of Antiangiogenesis

LYG-202 Inhibits Activation of Endothelial Cells and Angiogenesis Through CXCL12/CXCR7 Pathway in Breast Cancer

BML-111, a Lipoxin Receptor Agonist, Modulates the Immune Response and Reduces the Severity of Collagen-Induced Arthritis.

NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor Microenvironment

BML-111 Suppresses TGF-β1-induced Lung FIbroblast Activation Invitro and Decreases Experimental Pulmonary Fibrosis Invivo

BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo